Atria Wealth Solutions Inc. Takes $316,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

Atria Wealth Solutions Inc. bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,621 shares of the medical research company’s stock, valued at approximately $316,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EXAS. AMF Tjanstepension AB bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $724,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $49,000. First Trust Direct Indexing L.P. bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $402,000. Focus Financial Network Inc. bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $267,000. Finally, Chicago Partners Investment Group LLC boosted its position in shares of Exact Sciences by 1.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after acquiring an additional 158 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Price Performance

EXAS opened at $47.41 on Friday. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The business’s fifty day simple moving average is $53.93 and its 200-day simple moving average is $59.72. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of -8.51 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. On average, equities research analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EXAS. The Goldman Sachs Group decreased their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group decreased their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Jefferies Financial Group increased their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. TD Cowen increased their price target on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Citigroup decreased their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.94.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.